Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.
2.

Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania.

Tarimo EAM, Ambikile J, Munseri P, Bakari M.

PLoS One. 2019 Nov 8;14(11):e0224831. doi: 10.1371/journal.pone.0224831. eCollection 2019.

3.

Effect of dose reduction of supplemental zinc for childhood diarrhoea: study protocol for a double-masked, randomised controlled trial in India and Tanzania.

Somji SS, Dhingra P, Dhingra U, Dutta A, Devi P, Kumar J, Deb S, Semwal OP, Sazawal S, Manji K, Kisenge R, Bakari M, Aboud S, Liu E, Sudfeld C, Duggan CP, Ashorn P, Bahl R, Simon JL.

BMJ Paediatr Open. 2019 Apr 24;3(1):e000460. doi: 10.1136/bmjpo-2019-000460. eCollection 2019.

4.

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.

Nadai Y, Held K, Joseph S, Ahmed MIM, Hoffmann VS, Peterhoff D, Missanga M, Bauer A, Joachim A, Reimer U, Zerweck J, McCormack S, Cope AV, Tatoud R, Shattock RJ, Robb ML, Sandstroem EG, Hoelscher M, Maboko L, Bakari M, Kroidl A, Wagner R, Weber J, Pollakis G, Geldmacher C.

Front Immunol. 2019 Apr 24;10:717. doi: 10.3389/fimmu.2019.00717. eCollection 2019.

5.

Sialic acid levels in breast milk from HIV-positive Tanzanian women and impact of maternal diet.

Connor RI, Zain-Ul-Abideen M, Magohe AK, Brickley EB, Housman ML, Lyimo MA, Mchaki B, Maro I, Hendricks KM, Lukmanji Z, Matee M, Bakari M, Pallangyo K, Von Reyn CF.

AIDS. 2019 Mar 1;33(3):509-514. doi: 10.1097/QAD.0000000000002081.

PMID:
30702519
6.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

7.

Pre- and post-natal macronutrient supplementation for HIV-positive women in Tanzania: Effects on infant birth weight and HIV transmission.

Magohe A, Mackenzie T, Kimario J, Lukmanji Z, Hendricks K, Koethe J, Neke NM, Tvaroha S, Connor R, Waddell R, Maro I, Matee M, Pallangyo K, Bakari M, von Reyn CF; DarDar-2 Study Team.

PLoS One. 2018 Oct 11;13(10):e0201038. doi: 10.1371/journal.pone.0201038. eCollection 2018.

8.

CDKN2A Depletion Causes Aneuploidy and Enhances Cell Proliferation in Non-Immortalized Normal Human Cells.

Hélias-Rodzewicz Z, Lourenco N, Bakari M, Capron C, Emile JF.

Cancer Invest. 2018;36(6):338-348. doi: 10.1080/07357907.2018.1491588. Epub 2018 Aug 23.

PMID:
30136875
9.

Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania.

Tarimo EAM, Kakoko DCV, Kohi TW, Bakari M, Sandstrom E, Siyame D, Mhalu F, Kulane A.

BMC Public Health. 2018 Jul 21;18(1):905. doi: 10.1186/s12889-018-5835-5.

10.

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E.

Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.

11.

Evaluation of distance learning IMCI training program: the case of Tanzania.

Muhe LM, Iriya N, Bundala F, Azayo M, Bakari MJ, Hussein A, John T.

BMC Health Serv Res. 2018 Jul 13;18(1):547. doi: 10.1186/s12913-018-3336-y.

12.

Developing a multisectoral National Action Plan for Health Security (NAPHS) to implement the International Health Regulations (IHR 2005) in Tanzania.

Mghamba JM, Talisuna AO, Suryantoro L, Saguti GE, Muita M, Bakari M, Rusibamayila N, Ally M, Bernard J, Banda R, Mapunda M, Eidex R, Sreedharan R, Sliter K, Nikkari S, Saikat S, Lolong GPM, Verboom P, Yahaya AA, Chungong S, Rodier G, Fall IS.

BMJ Glob Health. 2018 Mar 9;3(2):e000600. doi: 10.1136/bmjgh-2017-000600. eCollection 2018. Review.

13.

Cholera Mortality during Urban Epidemic, Dar es Salaam, Tanzania, August 16, 2015-January 16, 20161.

McCrickard LS, Massay AE, Narra R, Mghamba J, Mohamed AA, Kishimba RS, Urio LJ, Rusibayamila N, Magembe G, Bakari M, Gibson JJ, Eidex RB, Quick RE.

Emerg Infect Dis. 2017 Dec;23(13). doi: 10.3201/eid2313.170529.

14.
15.

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.

Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, Nilsson C, Kaluwa B, Lueer C, Mwakatima M, Munseri PJ, Maboko L, Robb ML, Tovanabutra S, Kijak G, Marovich M, McCormack S, Joseph S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Bakari M, Kroidl A, Geldmacher C.

J Virol. 2017 Aug 24;91(18). pii: e00730-17. doi: 10.1128/JVI.00730-17. Print 2017 Sep 15.

16.

Notes from the Field: Ongoing Cholera Epidemic - Tanzania, 2015-2016.

Narra R, Maeda JM, Temba H, Mghamba J, Nyanga A, Greiner AL, Bakari M, Beer KD, Chae SR, Curran KG, Eidex RB, Gibson JJ, Handzel T, Kiberiti SJ, Kishimba RS, Lukupulo H, Malibiche T, Massa K, Massay AE, McCrickard LS, Mchau GJ, Mmbaga V, Mohamed AA, Mwakapeje ER, Nestory E, Newton AE, Oyugi E, Rajasingham A, Roland ME, Rusibamayila N, Sembuche S, Urio LJ, Walker TA, Wang A, Quick RE.

MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):177-178. doi: 10.15585/mmwr.mm6606a5. No abstract available.

17.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lyamuya EF, Tecleab T, Liakina V, Scarlatti G, Robb ML, Earl PL, Moss B, Wahren B, Mhalu F, Ferrari G, Sandstrom E, Biberfeld G.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):880-888. doi: 10.1089/AID.2016.0251. Epub 2017 Jan 27.

18.

The Influence of Community Members on Participation by Youth in an HIV Vaccine Trial in Tanzania.

Mbunda T, Tarimo EA, Chalamilla G, Bakari M, Sandström E, Kulane A.

PLoS One. 2016 Dec 20;11(12):e0168660. doi: 10.1371/journal.pone.0168660. eCollection 2016.

19.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, McCormack S.

PLoS One. 2016 May 18;11(5):e0155702. doi: 10.1371/journal.pone.0155702. eCollection 2016.

20.

Risk factors for small-for-gestational-age and preterm births among 19,269 Tanzanian newborns.

Muhihi A, Sudfeld CR, Smith ER, Noor RA, Mshamu S, Briegleb C, Bakari M, Masanja H, Fawzi W, Chan GJ.

BMC Pregnancy Childbirth. 2016 May 17;16:110. doi: 10.1186/s12884-016-0900-5.

21.

Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania.

Tarimo EA, Bakari M, Kakoko DC, Kohi TW, Mhalu F, Sandstrom E, Kulane A.

BMC Public Health. 2016 Feb 24;16:182. doi: 10.1186/s12889-016-2875-6.

22.

Auditory Impairments in HIV-Infected Children.

Maro II, Fellows AM, Clavier OH, Gui J, Rieke CC, Wilbur JC, Chambers RD, Jastrzembski BG, Mascari JE, Bakari M, Matee M, Musiek FE, Waddell RD, von Reyn CF, Palumbo PE, Moshi N, Buckey JC.

Ear Hear. 2016 Jul-Aug;37(4):443-51. doi: 10.1097/AUD.0000000000000276.

23.

Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.

Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM.

BMC Infect Dis. 2015 Aug 26;15:368. doi: 10.1186/s12879-015-1085-7.

24.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M.

PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015.

25.

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.

Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, Wahren B, Mhalu F, Sandström E, Biberfeld G, Ferrari G, Polonis VR.

PLoS One. 2015 Apr 14;10(4):e0118486. doi: 10.1371/journal.pone.0118486. eCollection 2015.

26.

Deficiencies of macronutrient intake among HIV-positive breastfeeding women in Dar es Salaam, Tanzania.

Kim F, Neke NM, Hendricks K, Wamsele J, Lukmanji Z, Waddell R, Maro I, Connor R, Mackenzie T, Matee M, Bakari M, Pallangyo K, von Reyn CF.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):569-72. doi: 10.1097/QAI.0000000000000352.

27.

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy U.

J Antimicrob Chemother. 2014 Dec;69(12):3311-9. doi: 10.1093/jac/dku286. Epub 2014 Aug 4.

PMID:
25096076
28.

Symptom-based screening tool in ruling out active tuberculosis among HIV-infected patients eligible for isoniazid preventive therapy in Tanzania.

Shayo GA, Minja LT, Egwaga S, Bakari M, Mugusi FM.

Trop Med Int Health. 2014 Jun;19(6):726-733. doi: 10.1111/tmi.12307. Epub 2014 Mar 24.

29.

Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania.

Tarimo EA, Munseri P, Aboud S, Bakari M, Mhalu F, Sandstrom E.

PLoS One. 2014 Mar 6;9(3):e90938. doi: 10.1371/journal.pone.0090938. eCollection 2014.

30.

Factors that influence the willingness of young adults in Dar es Salaam, Tanzania, to participate in phase I/II HIV vaccine trials.

Mbunda T, Bakari M, Tarimo EA, Sandstrom E, Kulane A.

Glob Health Action. 2014 Feb 25;7:22853. doi: 10.3402/gha.v7.22853. eCollection 2014.

31.

Auditory impairments in HIV-infected individuals in Tanzania.

Maro II, Moshi N, Clavier OH, MacKenzie TA, Kline-Schoder RJ, Wilbur JC, Chambers RD, Fellows AM, Jastrzembski BG, Mascari JE, Bakari M, Matee M, Musiek FE, Waddell RD, von Reyn CF, Buckey JC.

Ear Hear. 2014 May-Jun;35(3):306-17. doi: 10.1097/01.aud.0000439101.07257.ed.

32.

Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial.

Bakari M, Munseri P, Francis J, Aris E, Moshiro C, Siyame D, Janabi M, Ngatoluwa M, Aboud S, Lyamuya E, Sandström E, Mhalu F.

BMC Public Health. 2013 Dec 9;13:1149. doi: 10.1186/1471-2458-13-1149.

33.

Nutritional status of HIV-infected women with tuberculosis in Dar es Salaam, Tanzania.

Bakari M, Wamsele J, MacKenzie T, Maro I, Kimario J, Ali S, Dowla S, Hendricks K, Lukmanji Z, Neke NM, Waddell R, Matee M, Pallangyo K, von Reyn CF.

Public Health Action. 2013 Sep 21;3(3):224-9. doi: 10.5588/pha.13.0028.

34.

A qualitative study of perceived risk for HIV transmission among police officers in Dar es Salaam, Tanzania.

Tarimo EA, Kohi TW, Bakari M, Kulane A.

BMC Public Health. 2013 Aug 29;13:785. doi: 10.1186/1471-2458-13-785.

35.

Declining HIV-1 prevalence and incidence among Police Officers - a potential cohort for HIV vaccine trials, in Dar es Salaam, Tanzania.

Munseri PJ, Bakari M, Janabi M, Aris E, Aboud S, Hejdeman B, Sandstrom E.

BMC Public Health. 2013 Aug 6;13:722. doi: 10.1186/1471-2458-13-722.

36.

Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis.

Lahey T, Czechura T, Crabtree S, Arbeit RD, Matee M, Horsburgh CR, MacKenzie T, Bakari M, Pallangyo K, von Reyn CF.

J Infect Dis. 2013 Nov 15;208(10):1629-33. doi: 10.1093/infdis/jit396. Epub 2013 Aug 1.

38.

Increased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania.

Kabali C, Mtei L, Brooks DR, Waddell R, Bakari M, Matee M, Arbeit RD, Pallangyo K, von Reyn CF, Horsburgh CR.

Tuberculosis (Edinb). 2013 Jul;93(4):461-6. doi: 10.1016/j.tube.2013.01.001. Epub 2013 Mar 22.

39.

Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.

Lahey T, Mackenzie T, Arbeit RD, Bakari M, Mtei L, Matee M, Maro I, Horsburgh CR, Pallangyo K, von Reyn CF.

Clin Infect Dis. 2013 Jan;56(1):151-8. doi: 10.1093/cid/cis798. Epub 2012 Sep 12.

40.
41.

Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.

Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, Burhenne J, Lindquist L, Mugusi F, Sandstrom E, Aklillu E.

PLoS One. 2012;7(7):e40180. doi: 10.1371/journal.pone.0040180. Epub 2012 Jul 11.

42.

Molecular epidemiology of HIV-associated tuberculosis in Dar es Salaam, Tanzania: strain predominance, clustering, and polyclonal disease.

Adams LV, Kreiswirth BN, Arbeit RD, Soini H, Mtei L, Matee M, Bakari M, Lahey T, Wieland-Alter W, Shashkina E, Kurepina N, Driscoll JR, Pallangyo K, Horsburgh CR, von Reyn CF.

J Clin Microbiol. 2012 Aug;50(8):2645-50. doi: 10.1128/JCM.00624-12. Epub 2012 May 30.

43.

New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection.

von Reyn CF, Bakari M, Arbeit RD, Lahey T, Ramadhani A, Egwaga S.

Int J Tuberc Lung Dis. 2012 Jun;16(6):718-23. doi: 10.5588/ijtld.11.0444. Epub 2012 Apr 9. Review.

PMID:
22507085
44.

Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania.

Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, Lahey T, von Reyn F.

PLoS One. 2012;7(3):e32876. doi: 10.1371/journal.pone.0032876. Epub 2012 Mar 8.

45.

Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania.

Chillo P, Bakari M, Lwakatare J.

Cardiovasc J Afr. 2012 Mar;23(2):90-7. doi: 10.5830/CVJA-2011-060. Epub 2012 Feb 13.

46.

Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.

Mugusi SF, Ngaimisi E, Janabi MY, Mugusi FM, Minzi OM, Sasi PG, Bakari M, Lindquist L, Aklillu E, Sandstrom EG.

Antivir Ther. 2012;17(2):265-74. doi: 10.3851/IMP1956. Epub 2011 Nov 17.

PMID:
22293579
47.

Key considerations in scaling up male circumcision in Tanzania: views of the urban residents in Tanzania.

Francis JM, Kakoko D, Tarimo EA, Munseri P, Bakari M, Sandstrom E.

Tanzan J Health Res. 2012 Jan;14(1):61-7.

PMID:
26591748
48.

A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.

Tarimo EA, Thorson A, Kohi TW, Bakari M, Sandstrom E, Mhalu F, Kulane A.

BMC Infect Dis. 2011 Oct 24;11:283. doi: 10.1186/1471-2334-11-283.

49.

Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.

Kabali C, von Reyn CF, Brooks DR, Waddell R, Mtei L, Bakari M, Matee M, Pallangyo K, Arbeit RD, Horsburgh CR Jr.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1515-21, i. doi: 10.5588/ijtld.10.0788.

PMID:
22008766
50.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

Supplemental Content

Loading ...
Support Center